-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AstraZeneca China announced that it has obtained the exclusive right to promote the anti-tumor biopharmaceutical Boyounuo® (bevacizumab injection) of Boan Biologics, a subsidiary of Luye Pharmaceutical Group, in 21 provinces, cities, and autonomous regions in mainland China
.
The two parties will combine their respective advantages and resources in the field of market coverage and drug development to promote the expansion of anti-tumor biologics to the county market, and help more patients with non-small cell lung cancer and colorectal cancer benefit from China’s local anti-tumor biologics.
In the field of oncology, AstraZeneca is committed to providing diversified oncology treatment solutions, establishing a diversified product portfolio and channels through continuous innovation, continuously promoting changes in medical practice and changing patient experience
.
The cooperation with Boan Bio on bevacizumab injection involves the field of non-small cell lung cancer and metastatic colorectal cancer
AstraZeneca has a leading position in the county market in China, with a professional sales team for oncology products, abundant local commercial operation capabilities and extensive market coverage
.
Rooted in counties in China for many years, AstraZeneca has not only improved the availability of innovative medicines and provided solutions for integrated diagnosis and treatment throughout the course of disease management, AstraZeneca has also actively promoted the improvement of county diagnosis and treatment capabilities and assisted the construction of county medical systems with all parties in the society.
Wang Lei, Executive Vice President of AstraZeneca Global and President of International Business and China, said: "AstraZeneca has always been adhering to the concept of'patient-centered', actively working with resources from all parts of the society, and committed to let more county patients benefit from advanced Innovative treatments and solutions for the entire disease process and life cycle
.
Boan Bio is a comprehensive biopharmaceutical company with full industry chain capabilities.
Jiang Hua, CEO of Boan Biotech, said: “AstraZeneca has been deeply
involved in the field of tumor treatment and the county market for many years, and has extensive innovative resources and market coverage .
This strategic cooperation with AstraZeneca is an important part of the commercialization of Boyouno®.
The bevacizumab injection promoted by the two parties this time is an anti-tumor biological drug for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer
.
The product was recently approved for marketing by the China National Medical Products Administration
